Increased rates of contralateral prophylactic mastectomies (CPM) have been reported in patients undergoing genetic testing, regardless of the testing result.1 With both expanded access to genetic testing and increasing support for universal genetic testing of all patients with newly diagnosed breast cancer,2,3 an unintended outcome may be continued increases in CPM.